Legal History of Performance Enhancers: Steroids to Peptides

It All Started With Ben Johnson's Stanozolol

To understand why the legal position of peptides is so odd, you have to go back to September 24, 1988. That's the day Ben Johnson ran a 9.79-second 100-meter dash at the Seoul Olympics, and three days later, tested positive for stanozolol. This wasn't only about cheating anymore; Congress reframed it as a public health crisis threatening young Americans.

That public pressure led directly to the Anabolic Steroids Control Act of 1990. Before this, steroids were regular prescription drugs, like antibiotics. After 1990, they were classified as Schedule III controlled substances, the schedule the DEA now shares with ketamine and limited-codeine products such as Tylenol with codeine. This was a major shift. Possessing them without a valid prescription became a federal crime (under 21 U.S.C. 844, a first offense carries up to a year in prison), and distribution carried heavier penalties. The same bill extended the federal penalties for illegal steroid distribution to human growth hormone. It drove the market underground and set the precedent for how the U.S. government would deal with performance enhancers for the next 30 years: with a very big hammer.

The Prohormone Wars: When GNC Sold "Steroids"

With traditional steroids now in the controlled-substance category, the supplement industry got creative. Manufacturers looked at the new law, which covered a specific list of named compounds, and found a large gap. The idea was to sell a compound that wasn't on the list, but which the body converted into a banned steroid after you swallowed it.

Enter prohormones. Suddenly, you could walk into a GNC and buy androstenedione, the product famously spotted in Mark McGwire's locker in 1998. This was a thin veil. Buyers got a legal product that their own bodies turned into an anabolic steroid, and for years these products sat on ordinary store shelves.

Congress eventually caught on. The Anabolic Steroid Control Act of 2004 added androstenedione, the designer steroid tetrahydrogestrinone (THG) and related compounds to the list. The Designer Anabolic Steroid Control Act (DASCA) of 2014 went further. It added more named compounds and covered unlisted ones that are structurally similar to a listed steroid and made or promoted for testosterone-like effects. It also let the Attorney General add new compounds by order. The lesson here matters for understanding peptides: Congress has been reactive. It chases the chemists, passing new laws every decade or so to clean up the last generation's products. That cat-and-mouse pattern is what left room for peptides to emerge.

Peptides: The "Not-a-Steroid" Loophole

Peptides like ipamorelin or BPC-157 aren't treated the same way, and the reason is chemistry.

Since 2004, the Controlled Substances Act has defined an anabolic steroid as any drug or hormonal substance "chemically and pharmacologically related to testosterone," with a few named exclusions such as estrogens and corticosteroids. Peptides are chains of amino acids. They aren't structurally related to testosterone, and they work through different pathways, such as stimulating the growth hormone secretagogue receptor. None of the steroid acts reaches them.

This is where the familiar "For Research Purposes Only / Not for Human Consumption" label comes from. For years, sellers treated it as a legal shield: on paper, they were selling a raw chemical to a "researcher" for lab study, not a drug. Most buyers understood what was really happening. As of October 2026, FDA has made clear that the label doesn't settle anything. In warning letters dated March 31 and August 24, 2026, FDA told peptide sellers that despite their "research use only" statements, their websites showed the products were intended as drugs for human use. FDA pointed to the product descriptions and to the sale of bacteriostatic water for reconstituting injectable peptides, and it classed both as unapproved new drugs. Being outside the Controlled Substances Act isn't the same as being legal to sell for human use.

WADA vs. The DEA: Two Sets of Rules

Here's a point that trips up a lot of lifters. There's a big difference between what can lead to federal charges and what will simply get you banned from your sport.

The DEA enforces the Controlled Substances Act, and an unscheduled compound is mostly outside its remit; FDA and federal prosecutors use drug law instead. WADA (the World Anti-Doping Agency), on the other hand, sets the rules for any tested athlete. Its Prohibited List reaches far beyond federal criminal law.

As of October 2026, WADA's 2026 Prohibited List names GHRH analogues such as CJC-1295 and growth hormone secretagogues such as ipamorelin and GHRP-6 in section S2.2.4, prohibited at all times. BPC-157 is named in S0 (non-approved substances), and TB-500 sits in S2.3 as a thymosin-β4 derivative. For a tested powerlifter or CrossFit athlete, using ipamorelin is as much an anti-doping violation as using testosterone. But for a gym-goer who is never tested, one carries possible criminal liability while the other sits in a gray market. This split is the defining feature of the current rules.

Comparing the Legal Minefield

This table summarizes how each class is regulated as of October 2026.

The Gray Market Gets Crowded (And Scrutinized)

For about a decade, the peptide world was a quiet corner of the internet. As popularity grew, so did attention from regulators. FDA has cracked down not by asking Congress to schedule peptides, but by using powers it already has under federal drug law.

It can go after suppliers for selling "unapproved new drugs." Its argument is simple: if a website sells a vial of BPC-157 alongside claims about healing tendons, it isn't selling a "research chemical." It's selling a drug that hasn't been through FDA approval. The August 2026 letters named retatrutide and semaglutide along with SS-31 (elamipretide), PT-141 (bremelanotide) and tesamorelin.

Criminal cases have followed. In July 2026, a federal judge in Indiana sentenced Matthew Kawa, owner of Paradigm Peptides, to 70 months in prison after he pleaded guilty to selling unapproved drugs and illegally importing them, according to CBS News. Kawa admitted in his plea that he knew the "research use" products were being sold for human consumption. Prosecutors said that six products the company sold as SARMs, when tested by the government, all contained actual testosterone.

At the same time, the rules for pharmacies moved the other way. Around April 22, 2026, FDA removed 12 peptides from Category 2 (its "significant safety risks" group for 503A compounding) after their nominations were withdrawn; BPC-157 and TB-500 were among them. On July 23-24, 2026, FDA's Pharmacy Compounding Advisory Committee recommended six of them for the 503A bulks list, BPC-157 by an 8-6-1 vote, over the objections of FDA staff. The vote is advice only. FDA would have to complete notice-and-comment rulemaking before any could be lawfully compounded, and as of October 2026 we found no proposed rule.

This is the new front line. It isn't about making peptides illegal with one grand piece of legislation. Enforcement is squeezing the research-use-only supply chain, while a narrow route through compounding pharmacies may open for a few compounds. Our page on who peptide enforcement targets covers the enforcement side, and what could change next in peptide regulation tracks the pending decisions.

History Doesn't Repeat, But It Rhymes

The story of PED regulation has swung like a pendulum. A new class of compounds emerges in a legal gap. It gets popular. The media or a sports league makes a fuss about it. Congress holds hearings and eventually, slowly, acts. We saw the cycle with steroids in 1990 and with prohormones in 2004 and 2014.

Peptides haven't followed that script so far. Congress hasn't legislated on them, and even SARMs, which draw more political attention, were never scheduled: the SARMs Control Act of 2019 was referred to the Senate Judiciary Committee and went no further. Instead, the pressure has come from FDA action against sellers and from anti-doping rules for athletes. Meanwhile the 2026 compounding decisions point toward bringing a handful of peptides into regulated pharmacies rather than banning them.

The research-use-only market is a product of legislative lag and enforcement priorities, not a permanent feature of the law. Whether the next step is a compounding pathway for a few compounds or more prosecutions of sellers, history suggests today's gray market won't stay as it is for long. Our legal landscape overview explains how current rules apply to each compound class.